

ASX ANNOUNCEMENT

COMPANY SECRETARY APPOINTMENT AND RESIGNATIONS

SYDNEY, Tuesday, 31 March 2015: Cellmid Limited (ASX: CDY) wishes to advise shareholders that the Board of Directors has today appointed Mrs Lucy Rowe as Company Secretary. Mrs Rowe has worked in the financial services industry for the last fifteen years and currently holds and has held Company Secretarial positions with other listed companies.

The Board also announces the resignation of Mr Nicholas Falzon and Ms Jillian McGregor as joint Company Secretaries, effective as of today. The Directors thank Mr Falzon and Ms McGregor for their contribution to the Company during their tenure in these positions and wishes them well in their future endeavours.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company with lead drug candidates in oncology. The Company is developing innovative novel therapies and diagnostic tests for a number of cancer indications, in particular solid tumours. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel oncology target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see www.cellmid.com.au.

Investment in biotechnology companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.